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ABSTRACT 
Background: Cardiovascular disease (CVD) is a common comorbidity in people with asthma. 
However, safety concerns have caused heterogeneity in clinical guideline recommendations over the 
use of cardioselective beta-blockers in people with asthma and CVD, partly because risk in the 
general population has been poorly quantified. The aim of this study was to measure the risk of 
asthma exacerbations with beta-blockers prescribed to a general population with asthma and CVD. 
 
Methods: Linked data from the UK Clinical Practice Research Datalink was used to perform nested 
case-control studies among people with asthma and CVD matched on age, gender and calendar 
time. Adjusted incidence rate ratios (IRR) were calculated for the association between oral beta-
blocker use and moderate asthma exacerbations (rescue oral steroids) or severe asthma 
exacerbations (hospitalisation or death) using conditional logistic regression. 
 
Results: The cohort consisted of 35502 people identified with active asthma and CVD, of which 
14.1% and 1.2% were prescribed cardioselective and non-selective beta-blockers respectively during 
follow-up. Cardioselective beta-blocker use was not associated with a significantly increased risk of 
moderate or severe asthma exacerbations. Consistent results were obtained following sensitivity 
analyses and a self-controlled case series approach. In contrast, non-selective beta-blockers were 
associated with a significantly increased risk of moderate asthma exacerbations when initiated at 
low to moderate doses (IRR 5.16, 95%CI 1.83-14.54, p=0.002), and both moderate and severe 
exacerbations when prescribed chronically at high dose (IRR 2.68, 95%CI 1.08-6.64, p=0.033 and IRR 
12.11, 95%CI 1.02-144.11, p=0.048 respectively).  
 
Conclusions: Cardioselective beta-blockers prescribed to people with asthma and CVD were not 
associated with a significantly increased risk of moderate or severe asthma exacerbations and 
potentially could be used more widely when strongly indicated.  
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INTRODUCTION 
Cardiovascular disease (CVD) is an important comorbidity in people with asthma who are up to three 
times more likely to develop CVD than people without asthma.(1) Beta-blockers antagonise 
catecholamine-induced increases in heart rate, reduce blood pressure and improve left ventricular 
function, producing proven clinical benefits in people with CVD.(2, 3) Although beta-blockers may 
trigger exacerbations in susceptible people they are still prescribed to some people with asthma 
possibly because benefit is perceived to outweigh risk.(4, 5) Evidence from clinical trials suggest that 
cardioselective beta-blockers are reasonably well tolerated in asthma with meta-analyses suggesting 
that adverse respiratory response to beta-blockers varies according to the degree of 
cardioselectivity, dose of administration and individual response.(6, 7) However, existing clinical 
trials have generally assessed acute beta-blocker exposure under controlled conditions in relatively 
selected individuals with asthma. It is therefore uncertain whether these results are generalisable to 
real world asthma populations. 
 
Although certain asthma and cardiology guidelines now recommend that cardioselective beta-
blockers may be used on a case-by-case basis in people with asthma recommendations between 
clinical guidelines remain inconsistent with other national guidelines still recommending the 
avoidance of all beta-blockers in people with asthma.(8-11) This means that some people with 
asthma are being withheld beta-blockers despite strong clinical indications and proven benefits over 
their use .(12) These differences in recommendation may partly result from the risk of beta-blockers 
in people with asthma being poorly quantified, especially in real world populations were evidence is 
generally lacking. It is also increasingly recognised that some people may have the asthma/chronic 
obstructive pulmonary disease (COPD) overlap syndrome associated with a higher prevalence of 
CVD, making it particularly important to evaluate the safety of beta-blockers in asthma.(13) Evidence 
is therefore needed to evaluate the risk of beta-blockers in asthma from real life settings where 
routine beta-blocker prescribing occurs.  The aim of this study was to measure whether oral beta-
5 
 
blocker exposure increases the risk of asthma exacerbations in a general population with active 
asthma and CVD. 
 
METHODOLOGY 
Data source 
Data were extracted from the Clinical Practice Research Datalink (CPRD) which contains electronic 
medical records (EMRs) from >680 UK general practices and >5 million people. CPRD contains linked 
data on patient demographics, prescriptions, diagnoses, hospitalisations and deaths. Diagnoses are 
recorded using Read Codes, a hierarchical thesaurus of coded clinical terms used in UK primary 
care.(14) CPRD is linked to hospital admissions via the Hospital Episode Statistics (HES) database, and 
to deaths via the Office for National Statistics (ONS) database. HES and ONS diagnoses are recorded 
using the International Classification of Disease (ICD10) coding system. General practices and 
patients within CPRD meet defined quality standards to contribute data, and diagnoses within CPRD 
have been shown to have high validity.(15)  
 
Population 
The cohort included people ≥18 years with actively-treated asthma and actively treated CVD present 
in CPRD between 01/01/2000 and 31/12/2011. People with actively treated asthma and actively 
treated CVD were chosen so that controls were sampled from a more representative population. 
Subjects were eligible if they: were permanently registered with a general practice for ≥ϭ year; were 
from general practices linked to HES and ONS databases; were defined by CPRD as being acceptable 
for use in research (meaning their data had met quality standards); had a Read Code for asthma and 
a Read Code for a cardiovascular condition (ischaemic heart disease, chronic heart failure, cardiac 
arrhythmia, cerebrovascular disease, hypertension) (code list contained within Additional file 1). 
People with Read Codes for COPD, bronchiectasis or restrictive lung disease were excluded in order 
to prevent misclassification bias as beta-blockers are likely to be better tolerated in this population.  
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Cohort entry was defined as the first prescription date for a CVD medicine issued on or after the 
latest of: 01/01/2000; date of the first asthma medication; date of the patients 18th birthday; before 
the date of the patients 80th birthday. Asthma medication consisted of inhaled short-acting beta2-
agonists (SABA), inhaled corticosteroids (ICS), inhaled long-acting beta2-agonists (LABA), oral 
leukotriene antagonists, and oral methylxanthines.(16) Medication used for the management of CVD 
consisted of alpha blockers, beta-blockers (excluding those with propranolol because it is principally 
used for non-CVD conditions), calcium channel blockers, diuretics, nitrates and renin-angiotensin-
system inhibitors.(17) The cohort was followed until either of the following occurred: an asthma 
event; deregistration from the general practice; one year following the last asthma medication 
(thereby censoring people with inactive asthma or asthma that had resolved); end of CVD medical 
treatment; or end of the study period (31/12/2011). End of CVD medical treatment was defined by 
the last prescription date for a CVD medicine (plus a 90 day grace period) when 180 days had passed 
without any subsequent prescription for a CVD medicine. 
 
Study design and outcomes 
The primary analysis was a nested case-control design was used to more efficiently account for time-
varying confounders and drug exposure.(18) The nested case-control design assesses the risk of 
exposure vs. non-exposure among cases and controls and it is Ŷorŵal for Đases to appear ͚siĐker͛ 
than controls. (19) Two nested case-control studies were performed evaluating, 1) moderate asthma 
exacerbations and, 2) severe asthma exacerbations. Severe asthma exacerbations were defined as a 
hospitalisation for asthma (defined as admissions with ICD codes for asthma recorded as the primary 
reason for hospitalisation) or death from asthma. Moderate asthma exacerbations were identified 
by receipt of rescue oral steroids in primary care, defined as oral prednisolone prescriptions of less 
thaŶ Ϯ weeks duratioŶ usiŶg ≥5ŵg streŶgth taďlets. People with non-rescue oral steroids were 
excluded from this analysis to prevent outcome misclassification bias. For each outcome, the date of 
the first asthma event was the index date for case subjects.  
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Control selection 
Up to ten controls were randomly selected and matched to each case on age decile, gender and 
calendar year of cohort entry using incidence density sampling. The risk set date for controls was the 
index date for cases. With iŶĐideŶĐe deŶsity saŵpliŶg, ͚ĐoŶtrols͛ are a seleĐtioŶ of persoŶ-moments 
from individuals who have not experienced the event at the index date.(19)  In this regard, controls 
may be selected more than once, and people who subsequently become cases may be selected as 
controls at earlier time points. Two cases of severe asthma exacerbation (0.3%) and 8 cases of 
moderate asthma exacerbation (0.2%) were initially unmatched, but were included matched on 
gender and calendar year of cohort entry only and sensitivity analysis performed excluding these 
cases.  
 
Exposures 
Exposure to beta-blockers used for the management of CVD was measured by prescriptions issued 
prior to the index date. Beta-blocker exposure was categorised into: current acute exposure (defined 
as a prescription issued within 60 days of the index date and no previous prescription issued in days 
61-365 before the index date); current chronic exposure (defined as a prescription issued within 60 
days of the index date and ≥ϭ prescription issued in days 61-365 before the index date); and no 
exposure when there was no prescription issued in a 60 day risk window before the index dates. 
Among current users, beta-blocker exposure was evaluated by cardioselectivity and dose. Dose was 
stratified into low to moderate daily dose and high daily dose. High dose beta-blocker exposure was 
defined by daily doses greater than the following: acebutolol 200mg, atenolol 50mg, bisoprolol 5mg, 
carvedilol 25mg, celiprolol 200mg, metoprolol 100mg, nadolol 80mg, oxprenolol 80mg, pindolol 
10mg, sotalol 160mg, and timolol 10mg. 
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Confounders 
In recognition of the stepwise approach to asthma management and to account for the severity of 
asthma, analyses were adjusted for current use of asthma medication defined as a prescription for 
the following issued within 90 days of the index date: SABA; ICS; LABA; leukotriene antagonists; 
methylxanthines. As a sensitivity analysis, ICS was modelled by fluticasone-equivalent doses, 
Đategorised as high ;flutiĐasoŶe ≥ϭϬϬϬ μg/dayͿ, ŵoderate ;5ϬϬ–999 μg/dayͿ aŶd low ;< 5ϬϬ μg/dayͿ 
dose according to their relative topical potency (10). Additional risk adjustment was performed for: 
respiratory tract infection (RTI) diagnosed within 90 days of the index date; prior hospitalisation for 
asthma; prescription for CVD medicine use in the year prior to the index date (consisting of 
prescriptions for alpha blockers, calcium channel blockers, diuretics, nitrates and renin-angiotensin 
system medicine); exact age; smoking status; body mass index (BMI); index of multiple deprivation; 
Charlson comorbidity index; and attendance at a primary care asthma review in the year prior to the 
index date. 
 
Data analysis 
Conditional logistic regression was used to calculate odds ratios for the association between asthma 
exacerbations and beta-blocker exposure. Using an incidence density sampling approach, odds ratios 
represented unbiased estimators of incidence rate ratios (IRR). Adjusted rate differences were 
calculated for significant associations providing an absolute measure of effect.(19) Multiple 
imputation was used to impute missing data on height, weight and smoking status. The imputation 
model included all variables relating to clinical characteristics, asthma events, medication and beta-
blocker exposure. Multiple imputation used fully conditional specification, with linear regression for 
continuous variables and logistic regression for categorical variables with five imputations analysed 
usiŶg ‘uďiŶ͛s rules.(20) Analysis was carried out using SPSSv21 and STATAv13. 
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Sensitivity analyses and secondary self-controlled case series analysis 
Sensitivity analyses were performed for the primary analysis: modelling ICS by dose; excluding cases 
not originally matched on age; excluding people hospitalised within the risk period (assessing for 
potential immeasurable time bias)(21); excluding people over the age of 40 years who smoked 
(assessing for potential misclassification with undiagnosed or unrecorded COPD); using a complete 
case analysis; using a 30 and 90 day risk window (assessing whether risk attenuated over time and 
because the exact date patients started taking their medication was unknown). Furthermore we 
evaluated the association between nitrate exposure and risk of asthma exacerbations in the form of 
a negative control.  
 
As a secondary analysis a self-controlled case series with adjustment for time-varying confounders 
was performed to further measure the safety of acute cardioselective beta-blocker exposure and the 
risk of moderate asthma exacerbations (16). In contrast to the nested case control study, the self-
controlled case series is a within-person design whereby the patient acts as their own control, 
controlling for all fixed-confounders. Incidence rate ratios were calculated using conditional Poisson 
regression. Full details of the self-controlled case series approach are contained in Additional file 4. 
 
RESULTS 
The cohort consisted of 35502 people with actively treated asthma and CVD (mean age 60.1 years, 
59.7% women). During follow-up, cardioselective beta-blockers were prescribed to 5017 patients 
(14.1%) and non-selective beta-blockers were prescribed to 407 patients (1.2%). Cardioselective 
beta-blocker exposure consisted mainly of atenolol (7.9%) and bisoprolol (5.4%), whilst non-selective 
beta-blocker exposure consisted mainly of sotalol (0.6%) and carvedilol (0.4%). A total of 608 severe 
asthma exacerbations (incidence 4.4 per 1000 person-years) and 4234 moderate asthma 
exacerbations (incidence 50.4 per 1000 person years) occurred during follow up (mean 3.5 years). 
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The 608 cases of severe asthma exacerbation were matched to 6048 controls and the 4234 cases of 
moderate asthma exacerbation were matched to 41881 controls, selected from the cohort risk-sets 
(table 1). Cases and controls were well matched on age, gender and duration of follow-up. 
 
Cardioselective beta-blocker exposure 
Incidence rate ratios for moderate and severe asthma exacerbations associated with cardioselective 
beta-blocker exposure according to dose are presented in table 2. Cardioselective beta-blocker 
exposure was not significantly associated with an increased risk of moderate asthma exacerbations  
 (IRR 0.97, 95%CI 0.85-1.11, p=0.658) or of severe asthma exacerbations (IRR 0.87, 95%CI 0.57-1.35, 
p=0.540). Risk of moderate asthma exacerbations was not significantly increased with low to 
moderate dose cardioselective beta-blocker exposure (IRR 0.96, 95%CI 0.83-1.10, p=0.544) or high 
dose cardioselective beta-blocker exposure (IRR 1.08, 95%CI 0.82-1.42, p=0.600). Similarly, risk of 
severe asthma exacerbations was not significantly increased with low to moderate dose 
cardioselective beta-blocker exposure (IRR 0.85, 95%CI 0.53-1.36, p=0.501) or high-dose dose 
cardioselective beta-blocker exposure (IRR 0.96, 95%CI 0.33-2.84, p=0.943). When further evaluated 
by dose and duration of exposure, risk of moderate or severe asthma exacerbations was not 
significantly increased with either acute or chronic cardioselective beta-blocker exposure (table 3). 
 
Non-selective beta-blocker exposure 
High-dose non-selective beta-blocker exposure was associated with a significantly increased rate of 
moderate asthma exacerbations (IRR 2.67, 95%CI 1.08-6.62, p=0.034) and of severe asthma 
exacerbations (IRR 12.11, 95%CI 1.02-144.11, p=0.048), with adjusted rate differences of 63.2 (95%CI 
25.7-156.4) and 27.0 (95%CI 2.3-337.7) per 1000 person-years respectively (table 2). For severe 
asthma exacerbations, high dose non-selective beta-blocker exposure consisted entirely of chronic 
exposure. In contrast, low to moderate dose non-selective beta-blocker exposure was not associated 
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with a significantly increased relative incidence of moderate (IRR 1.24, 95%CI 0.80-1.91, p=0.336) or 
severe asthma exacerbations (IRR 1.19, 95%CI 0.31-4.53, p=0.799). 
 
When evaluated by dose and duration of exposure, the relative incidence of moderate asthma 
exacerbations was significantly increased with acute low to moderate dose non-selective beta-
blocker exposure (IRR 5.16, 95%CI 1.83-14.54, p=0.002), with an adjusted rate difference of 134.5 
(95%CI 25.9-370.6) per 1000 person years (table 3). In contrast, chronic low to moderate dose non-
selective beta-blocker exposure was not associated with an increased risk of moderate (IRR 0.99, 
95%CI 0.60-1.62, p=0.954) or severe (IRR 1.22, 95%CI 0.32-4.67, p=0.773) asthma exacerbations. 
 
Sensitivity analyses and secondary self-controlled case series analysis 
Sensitivity analyses for the primary analysis were consistent with the main findings showing no 
significantly increased risk of moderate or severe asthma exacerbations associated with 
cardioselective beta-blocker exposure, an increased risk of moderate asthma exacerbations 
associated with high dose and acute low to moderate dose non-selective beta-blocker exposure, and 
an increased risk of severe asthma exacerbations associated with high dose non-selective beta-
blocker exposure (Additional file 2 and 3). When nitrate exposure was used as a negative control in 
the primary analysis, there was no significant increased risk of moderate or severe asthma 
exacerbations associated with acute or chronic nitrate exposure (table 4).  
 
The self-controlled case series assessing the risk associated with acute cardioselective beta-blocker 
exposure produced consistent findings with no significantly increased risk of moderate asthma 
exacerbations when using a 30 day, 60 day or 90 day acute risk window following cardioselective 
beta-blocker initiation (IRR 1.01, 95%CI 0.66-1.54 for a 30 day risk window, IRR 0.99, 95%CI 0.72-1.38 
for a 60 day risk window and IRR 0.93, 95%CI 0.69-1.25 for a 90 day risk window) (please see 
Additional file 4 for further details). 
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DISCUSSION 
Although managing comorbidity is the norm in modern medicine, clinical uncertainty still exists 
around whether to prescribe cardioselective beta-blockers to people with asthma and CVD. Our 
findings suggest that the adverse respiratory response to beta-blockers in asthma depends partly 
upon cardioselectivity, dose and duration of exposure. Among our population with active asthma 
and CVD, oral cardioselective beta-blocker exposure was not associated with a significantly 
increased risk of asthma exacerbations. In contrast, oral non-selective beta-blocker exposure was 
associated with a significantly increased the risk of asthma exacerbations when initiated at low to 
moderate doses, and when prescribed chronically at high doses. 
 
Apparent differences in risk between acute and chronic low to moderate dose oral non-selective 
beta-blocker exposure could be due to attenuation of risk associated with beta2-adrenoceptor up-
regulation, as suggested by studies evaluating chronic dosing effects of oral beta-blockers in asthma, 
or survival bias whereby people are more likely to receive longer-term therapy if they tolerate acute 
exposure.(22)  Studies investigating chronic oral non-selective beta-blocker exposure in asthma have 
typically used selected populations of well controlled asthmatics initiating oral non-selective beta-
blockers at low dose, using inhaled muscarinic antagonist cover to prevent bronchoconstriction from 
unopposed cholinergic tone.(23) Our previous meta-analysis of randomised controlled trials 
demonstrated that acute oral non-selective beta-blocker exposure caused mean falls in forced 
expiratory volume in one second (FEV1) of 10%, an increase in respiratory symptoms affecting one in 
thirteeŶ aŶd falls iŶ FEVϭ of ≥ϮϬ% affeĐtiŶg oŶe iŶ ŶiŶe people with asthma.(6) It has also been 
demonstrated that acute non-selective beta-blocker eye drop exposure caused mean falls in FEV1 of 
ϭϭ% aŶd falls iŶ FEVϭ of ≥ϮϬ% affeĐtiŶg oŶe iŶ three people with asthŵa iŶ ĐliŶiĐal trials, aŶd aŶ 
increased risk of moderate asthma exacerbations in routine practice. (24) Although it appears that 
some people with asthma do tolerate non-selective beta-blockers, risk of bronchoconstriction is 
therefore much greater, and response to SABA rescue therapy is significantly blunted with fatal 
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cases have been reported following treatment of myocardial infarction.(6, 25) Given 
recommendations for rapid treatment of myocardial infarction, in such instances it is important not 
to overlook proper assessment of patients to identify those with comorbid asthma (26). Findings 
from our current study therefore support established recommendations that non-selective beta-
blockers should not be prescribed for the management of CVD in people with asthma.  
 
Our previous meta-analysis of randomised controlled trials also demonstrated that acute oral 
cardioselective beta-blockade (consisting largely of moderate to high dose exposure) caused 
asymptomatic mean falls in FEV1 of 7%, and asymptomatic falls in FEV1 of ≥ϮϬ% affeĐtiŶg oŶe iŶ 
eight people with asthma. Our real world observational study found that oral cardioselective beta-
blocker use in people with active asthma and CVD was not associated with a significantly increased 
risk of moderate or severe asthma exacerbations.(6) Therefore, these findings do not support 
recommendations present in some asthma and CVD guidelines that all beta-blockers should be 
avoided in people with asthma when strong clinical indications exist.(10, 11) In this regard, the 
overall benefit-risk of using beta-blockers in people with asthma should be taken into account. This 
study also suggests that cardioselective beta-blockers should not be routinely discontinued in people 
with asthma if already established on cardioselective beta-blockers providing they are appropriately 
indicated. This is important for prescribing safety interventions that may class and target the use of 
cardioselective beta-blockers in people with asthma as high risk.(27) 
 
Although no significant increase in exacerbations occurred with acute high dose cardioselective 
beta-blocker exposure, confidence intervals were wide and our previous meta-analysis of 
randomised controlled trials highlighted a dose response relationship may occur with acute 
cardioselective beta-blocker exposure.(6) As such, we cannot exclude the possibility that a higher 
risk of exacerbation exists in such comparisons.  For this reason, if cardioselective beta-blockers are 
to be considered in people with asthma, they should realistically only be initiated at low dose with 
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gradual dose titration, ensuring the availability of reliever therapy that is still reasonably effective 
during acute cardioselective beta-blockade should symptoms develop.(6) Regardless of comorbid 
asthma, initiating beta-blockers at low dose with gradual dose titration should be routinely 
recommended to prevent episodes of hypotension and bradycardia. Prior to considering 
cardioselective beta-blockers in people with asthma and CVD however, a benefit-risk assessment 
would be prudent ideally taking into account patient preference.  
 
The mean age of patients in our study was 62 years such that some patients might have ACOS, 
raising the important related question as to the safety of beta-blockers in COPD where the burden of 
CVD is higher. Current evidence suggests that patients with COPD taking long term beta-blockers 
have reduced exacerbations and reduced mortality.(28) Despite this observation, beta-blockers 
appear to be underused in people with COPD and heart failure. (29, 30) Patients with COPD may be 
less likely to bronchoconstrict from beta-blockade because of greater fixed airflow obstruction and 
attenuated beta2-adrenoceptor responsiveness, which may vary depending on the asthmatic 
component. Nonetheless our data are reassuring for patients taking cardioselective beta-blockers 
for the management of CVD irrespective of having pure asthma or asthma-COPD overlap syndrome. 
 
This study has several limitations. First, not all types of beta-blocker exposure could be properly 
assessed including acute high dose non-selective beta-blocker exposure were risk is likely to be 
greater. Given current guideline recommendations surrounding the use of non-selective beta-
blockers in asthma, it is unsurprising that acute high dose non-selective beta-blocker exposure in 
people with asthma and CVD was rare. However, our principle aim was to evaluate cardioselective 
beta-blocker exposure to better inform their use in people with asthma and CVD where there is an 
unmet need. In this context, identifying an increased risk from non-selective beta-blocker exposure 
helps to act as a positive control. Second, we cannot exclude the possibility that some people had a 
degree of fixed air-flow obstruction because lung function data was not routinely available and 
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residual confounding may exist which is possible in all observational studies. However, several 
sensitivity analyses were conducted with results in keeping with the main analysis. Third, 
prescription dates were used as a proxy for exposure and it is uncertain exactly when patients 
commenced their medication. Fourth, we cannot exclude a degree of selection bias among 
asthmatics prescribed beta-blockers in our cohort potentially affecting the generalisability of results 
to all people with asthma. However, the crude prevalence of beta-blocker prescribing between cases 
and controls was very similar, and some people with asthma were still prescribed non-selective beta-
blockers shown to be associated with a significantly increased risk of asthma exacerbations 
supporting our findings. Fifth, observational studies may be prone to bias. Our primary analysis used 
a nested case control study, a between-person study design. We therefore performed a self-
controlled case series, a within person design were the patient acts as their own control, assessing 
acute cardioselective beta-blocker exposure with consistent results. Furthermore, we evaluated a 
negative control using nitrate exposure. Lastly, outcomes and exposures relied upon electronic 
prescribing and coding, and it remains possible that not all of these were identified. Nevertheless, 
hospital discharges are routinely captured electronically in the UK and almost all community 
prescriptions are issued electronically from general practice, including those initiated by hospital 
specialists.  
 
CONCLUSION 
In conclusion, this study suggests that the adverse respiratory response from beta-blockers in people 
with asthma and CVD varies according to cardioselectivity, dose and duration of exposure. In 
contrast to oral non-selective beta-blockers, oral cardioselective beta-blocker exposure was not 
associated with a significantly increased risk of asthma exacerbations and potentially should be 
considered more widely in people with strong clinical indications. 
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LIST OF ABBREVIATIONS 
COPD Chronic obstructive pulmonary disease 
CVD Cardiovascular disease 
FEV1 Forced expiratory volume in 1 second 
HES Hospital episodes statistics 
ICD International classification of disease 
ICS Inhaled corticosteroid 
IRR Incidence rate ratio 
LABA Long-acting beta2-agonist 
ONS Office for national statistics 
RTI Respiratory tract infection 
SABA Short-acting beta2-agonist 
95%CI 95% confidence interval 
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Table 1. Characteristics of cases and controls for severe and moderate asthma exacerbations. 
 
 
 
Severe asthma 
exacerbations 
Moderate asthma 
exacerbation  
Cases Controls Cases Controls 
Number of people 608 6048 4234 41881 
Female gender, no. (%) 428 (70.4) 4261 (70.5) 2815 (66.5) 27898 (66.6) 
Age (years), mean  ± SD 62.4 ±13.4 62.5 ± 13.3 62.8 ± 11.8 62.9 ± 11.7 
Years of follow-up, mean ± SD 2.9 ± 2.9 2.9 ± 2.9 2.0 ± 2.5 2.0 ± 2.5 
Asthma medication use,* no. (%)     
-SABA 482 (79.3) 3631 (60.0) 2809 (66.3) 22916 (54.7) 
-ICS 492 (80.1) 4336 (71.7) 3060 (72.3) 27236 (65.0) 
-LABA 339 (55.8) 1905 (31.5) 1407 (33.2) 9975 (23.8) 
-Leukotriene antagonists 67 (11.0) 193 (3.2) 108 (2.6) 731 (1.8) 
-Methylxanthines 52 (8.6) 107 (1.7) 80 (1.9) 564 (1.4) 
-Oral corticosteroids 270 (44.4) 417 (6.9) n/a n/a 
Cardiac medication use,¥ no. (%)     
-Alpha blockers 68 (11.2) 590 (9.8) 395 (9.3) 3774 (9.0) 
-Beta-blockers 47 (7.7) 533 (8.8) 425 (10.0) 4628 (11.1) 
-Calcium channel blockers 293 (48.2) 2755 (45.6) 1775 (41.9) 18708 (44.7) 
-Diuretics 333 (54.8) 3210 (53.1) 2185 (51.6) 21240 (50.7) 
-Nitrates 97 (16.0) 653 (10.8) 495 (11.7) 4760 (11.4) 
-Renin angiotensin system inhibitors 404 (66.5) 3973 (65.7) 2679 (63.3) 26344 (62.3) 
Charlson comorbidity index, ± SD 2.0 ± 1.5 1.9 ± 1.4 1.8 ± 1.3 2.0 ±1.5 
Body mass index, ± SD 31.0 ± 7.0 30.1 ± 6.3 30.2 ± 6.3 29.7 ± 6.0 
Smoking status, no. (%)     
-Current smoker 63 (10.4) 566 (9.4) 444 (10.5) 4132 (9.9) 
-Non-smoker 516 (84.9) 5314 (87.9) 3664 (86.5) 36256 (86.5) 
-Missing   29 (4.8) 168 (2.8) 126 (3.0) 1493 (3.6) 
Respiratory tract infection,* no. (%) 110 (18.1) 398 (6.6) 597 (14.1) 2001 (4.8) 
Ever hospitalised for asthma, no. (%) 84 (13.8) 120 (2.0) 115 (2.7) 602 (1.5) 
Primary care asthma review, ¥ no. (%) 283 (46.6) 2917 (48.2) 2104 (49.7) 18905 (45.1) 
 
No. = number, SD = standard deviation, SABA = short-acting beta2-agonists, ICS = inhaled corticosteroids, LABA 
= long-acting beta2-agonists, BMI = Body mass index. * In the 90 days prior to the index date.  ¥ In the year 
prior to the index date.  n/a=not applicable.
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Table 2. Incidence rate ratios for the association between beta-blocker exposure and asthma exacerbations by dose. 
*Exposed cases/controls = exposed within the 60 day risk window. IRR = Incidence Rate Ratios. Adjusted for asthma medication use in the 90 days prior to the index date; 
respiratory tract infection in the 90 days prior to the index date; prior hospitalization for asthma; type of CVD medicine use in the year prior to the index date; exact age; 
smoking status; body mass index; social deprivation; Charlson comorbidity index; and primary care asthma review in the year prior to the index date. 
 
 
 Cardioselective beta-blockers Non-selective beta-blockers 
 Exposed Exposed Crude Adjusted Exposed Exposed Crude Adjusted 
 Cases Controls IRR IRR 95% CI p-value Cases Controls IRR IRR 95% CI p-value 
Any exposure              Severe exacerbation 27 466 0.72 0.87 0.57-1.35 0.540 9 51 1.29 1.66 0.53-5.35 0.398  Moderate exacerbation 357 3956 0.89 0.97 0.85-1.11 0.658 35 309 1.33 1.41 0.95-2.08 0.088 
Low dose              Severe exacerbation 23 388 0.70 0.85 0.53-1.36 0.501 8 44 1.04 1.19 0.31-4.53 0.799  Moderate exacerbation 283 3256 0.87 0.96 0.83-1.10 0.544 29 271 1.19 1.24 0.80-1.91 0.336 
High dose               Severe exacerbation 4 82 0.85 0.96 0.33-2.84 0.943 1 7 5.00 12.11 1.02-144.11 0.048  Moderate exacerbation 79 733 0.99 1.08 0.82-1.42 0.600 6 39 2.50 2.67 1.08-6.62 0.034 
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Table 3. Incidence rate ratios for the association between beta-blocker exposure and asthma exacerbations by dose and duration of exposure. 
*Exposed cases/controls = exposed within the 60 day risk window. IRR = Incidence Rate Ratios. Adjusted for asthma medication use in the 90 days prior to the index date; 
respiratory tract infection in the 90 days prior to the index date; prior hospitalization for asthma; type of CVD medicine use in the year prior to the index date; exact age; 
smoking status; body mass index; social deprivation; Charlson comorbidity index; and primary care asthma review in the year prior to the index date. Empty cells (-) = 
inestimable due to lack of corresponding beta-blocker exposure among cases and controls. *Severe asthma exacerbations associated with acute non-selective beta-blocker 
exposure inestimable due to lack of exposure. 
 
 Cardioselective beta-blockers Non-selective beta-blockers 
 Exposed Exposed Crude Adjusted Exposed Exposed Crude Adjusted 
 Cases Controls IRR IRR 95% CI p-value Cases Controls IRR IRR 95% CI p-value 
Low to moderate dose              
Acute              Severe exacerbation 4 28 1.41 1.47 0.44-4.97 0.532 0 2 - - - -  Moderate exacerbation 19 255 1.02 1.04 0.64-1.70 0.865 6 12 5.19 5.16 1.83-14.54 0.002 
Chronic              Severe exacerbation 19 360 0.63 0.81 0.48-1.35 0.409 8 42 1.11 1.22 0.32-4.67 0.773  Moderate exacerbation 264 3031 0.86 0.95 0.82-1.10 0.517 23 259 0.86 0.99 0.60-1.62 0.954 
High dose              
Acute               Severe exacerbation 1 6 1.67 2.76 0.32-23.78 0.347 0 0 - - - -  Moderate exacerbation 2 51 0.49 0.55 0.13-2.31 0.416 0 0 - - - - 
Chronic              Severe exacerbation 7 63 0.73 0.82 0.24-2.82 0.754 1 7 5.00 12.04 1.01-143.48 0.049  Moderate exacerbation 77 682 1.03 1.11 0.84-1.47 0.339 6 39 2.50 2.68 1.08-6.64 0.033 
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Table 4. Risk of moderate and severe asthma exacerbations using a negative control with nitrate exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Exposed cases/controls = exposed within the 60 day risk window. IRR = Incidence Rate Ratios. Adjusted for asthma medication use in the 90 days prior to the index date; respiratory tract 
infection in the 90 days prior to the index date; hospitalization for asthma in the year prior to the index date; type of CVD medicine use in the year prior to the index date; exact age; smoking 
status; body mass index; social deprivation; Charlson comorbidity index; and primary care asthma review in the year prior to the index date.  
 
 Nitrates 
 Exposed Exposed Crude Adjusted 
 Cases Controls IRR IRR 95% CI p-value 
Any exposure        Severe exacerbation 65 408 1.68 1.19 0.86-1.65 0.287  Moderate exacerbation 329 2896 1.14 1.10 0.97-1.25 0.131 
Acute exposure        Severe exacerbation 5 45 1.16 1.36 0.50-3.69 0.550  Moderate exacerbation 40 343 1.16 1.14 0.81-1.59 0.600 
Chronic exposure         Severe exacerbation 60 363 1.75 1.18 0.84-1.65 0.463  Moderate exacerbation 289 2553 1.14 1.10 0.96-1.26 0.172 
